In Silico Study of SARS-CoV-2 Vaccine Candidate: Spike Glycoprotein
Keywords:Allergenicity Prediction, COVID-19, In Silico Cloning, Toxicity Prediction, Vaccine.
This study aimed to perform the analysis of toxicity prediction, allergenicity prediction, and in silico cloning
of peptides originated from SARS-CoV-2 spike glycoprotein in the previous study. Allergenicity prediction
employed AllerPred to predict the non-allergen peptides and toxicity prediction performed using ToxinPred.
Then, this study designed the in silico cloning of SARS-CoV-2 spike glycoprotein with pET-28a(+) using
SnapGene software. Therefore, this study successfully constructed the SARS-CoV-2 vaccine candidate via
in silico method. Therefore, these data could be used to design a peptide-based vaccine against SARSCoV-2. However, the advanced study is recommended confirmation, such as in vitro and in vivo study
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Re use and mixing of content policy- We follow Creative Commons Licence Policy. We follow CC BY. Please refer below for all details
This license lets others distribute, remix, adapt, and build upon our work, even commercially, as long as they credit us for the original creation.
- The journal allows readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to retain publishing rights without restrictions